Log in to your Inderes Free account to see all free content on this page.
SenzaGen
6.8
SEK
0 %
SENZA
First North Stockholm
Medical Equipment & Services
Health Care
Less than 1K followers
0%
-1.45%
-2.86%
-9.33%
-3.55%
-2.3%
-35.85%
-62.01%
-83.9%
Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund.
Read moreMarket cap
200.63M SEK
Turnover
234.53K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
13.2.
2025
Annual report '24
ShowingAll content types
SenzaGen’s interim report January–September 2024: Strong quarter with over 30% growth
SenzaGen will present at the BioStock Life Science Summit, November 21
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio